Autophagy In Heart Failure: Insights Into Mechanisms And Therapeutic Implications

Research Summary

A review of autophagy — the cell’s recycling process that rapamycin and fasting activate — in heart failure, and of the drugs that turn it up or down in cardiac disease models.

Who Or What Was Studied?

Published experiments rather than a new study: genetically modified mice (knockouts of Atg5, Atg7, Lamp2, Becn1 and others) and pharmacological studies in animal models of myocardial infarction, pressure overload, diabetic cardiomyopathy and drug-induced cardiotoxicity, together with observations in human heart tissue.

What Did The Research Show?

• mTOR complex 1 phosphorylates Ulk1 and Atg13 to keep autophagy switched off, so rapamycin — which blocks mTORC1 — is a standard laboratory autophagy inducer.
• In mice, removing baseline autophagy in the heart (for example Atg5 or Lamp2 knockouts) causes cardiomyopathy, contractile dysfunction and premature death, so some baseline autophagy is needed for normal cardiac function.
• In myocardial infarction and reperfusion models the inducers rapamycin and metformin reduced infarct size, while blocking autophagy with 3-methyladenine or bafilomycin A1 enlarged it.
• In diabetic cardiomyopathy the genetic and pharmacological evidence points in opposite directions: mice with reduced autophagic flux had better cardiac function, whereas resveratrol, trehalose and metformin reduced fibrosis and improved function.
• In doxorubicin cardiotoxicity autophagy markers rise while autophagic flux is blocked; starvation before treatment, or rapamycin, resveratrol or metformin, partly restored flux and protected the heart.

Limitations And Interpretation

• This is a review of animal and cell models; no new human trial results are reported, and the authors state that no autophagy-specific drugs are clinically available.
• The direction of the effect depends on context — more autophagy is protective in some models and harmful in others — so the review does not recommend activating or blocking autophagy in patients.
• Most drugs discussed (rapamycin, metformin, resveratrol, chloroquine) act on several targets, so their cardiac effects cannot be attributed to autophagy alone.